BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 36586476)

  • 1. Association between metabolic dysfunction-associated fatty liver disease and supraventricular and ventricular tachyarrhythmias in patients with type 2 diabetes.
    Mantovani A; Csermely A; Taverna A; Cappelli D; Benfari G; Bonapace S; Byrne CD; Targher G
    Diabetes Metab; 2023 Mar; 49(2):101416. PubMed ID: 36586476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonalcoholic Fatty Liver Disease Is Associated With Ventricular Arrhythmias in Patients With Type 2 Diabetes Referred for Clinically Indicated 24-Hour Holter Monitoring.
    Mantovani A; Rigamonti A; Bonapace S; Bolzan B; Pernigo M; Morani G; Franceschini L; Bergamini C; Bertolini L; Valbusa F; Rigolon R; Pichiri I; Zoppini G; Bonora E; Violi F; Targher G
    Diabetes Care; 2016 Aug; 39(8):1416-23. PubMed ID: 27222503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations of metabolic dysfunction-associated fatty liver disease and hepatic fibrosis with bone mineral density and risk of osteopenia/osteoporosis in T2DM patients.
    Zhang W; Li Y; Li S; Zhou J; Wang K; Li Z; Chen N; Chen X
    Front Endocrinol (Lausanne); 2023; 14():1278505. PubMed ID: 38116314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus non-alcoholic fatty liver disease: a longitudinal cohort analysis.
    Muthiah M; Ng CH; Chan KE; Fu CE; Lim WH; Tan DJH; Nah B; Kong G; Xiao J; Yong JN; Tan B; Syn N; Wang JW; Sayed N; Tan E; Chew NW; Dan YY; Siddiqui MS; Sanyal AJ; Noureddin M
    Ann Hepatol; 2023; 28(1):100762. PubMed ID: 36182031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Metabolic Dysfunction-Associated Fatty Liver Disease With Left Ventricular Diastolic Function and Cardiac Morphology.
    Peng D; Yu Z; Wang M; Shi J; Sun L; Zhang Y; Zhao W; Chen C; Tang J; Wang C; Ni J; Wen W; Jiang J
    Front Endocrinol (Lausanne); 2022; 13():935390. PubMed ID: 35928895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-invasive screening, staging and management of metabolic dysfunction-associated fatty liver disease (MAFLD) in type 2 diabetes mellitus patients: what do we know so far ?
    Binet Q; Loumaye A; Preumont V; Thissen JP; Hermans MP; Lanthier N
    Acta Gastroenterol Belg; 2022; 85(2):346-357. PubMed ID: 35709779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MAFLD and risk of CKD.
    Sun DQ; Jin Y; Wang TY; Zheng KI; Rios RS; Zhang HY; Targher G; Byrne CD; Yuan WJ; Zheng MH
    Metabolism; 2021 Feb; 115():154433. PubMed ID: 33212070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic-associated fatty liver disease and the risk of cardiovascular disease.
    Zhang P; Dong X; Zhang W; Wang S; Chen C; Tang J; You Y; Hu S; Zhang S; Wang C; Wen W; Zhou M; Tan T; Qi G; Li L; Wang M
    Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102063. PubMed ID: 36494073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High liver fibrosis scores in metabolic dysfunction-associated fatty liver disease patients are associated with adverse atrial remodeling and atrial fibrillation recurrence following catheter ablation.
    Decoin R; Butruille L; Defrancq T; Robert J; Destrait N; Coisne A; Aghezzaf S; Woitrain E; Gouda Z; Schino S; Klein C; Maboudou P; Brigadeau F; Klug D; Vincentelli A; Dombrowicz D; Staels B; Montaigne D; Ninni S
    Front Endocrinol (Lausanne); 2022; 13():957245. PubMed ID: 36120456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations of sex-related and thyroid-related hormones with risk of metabolic dysfunction-associated fatty liver disease in T2DM patients.
    Lu W; Li S; Li Y; Zhou J; Wang K; Chen N; Li Z
    BMC Endocr Disord; 2024 Jun; 24(1):84. PubMed ID: 38849804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between Non-Alcoholic Steatohepatitis and Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Mellitus.
    Lee H; Kim G; Choi YJ; Huh BW; Lee BW; Kang ES; Cha BS; Lee EJ; Lee YH; Huh KB
    Diabetes Metab J; 2020 Apr; 44(2):267-276. PubMed ID: 30877708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan.
    Yoneda M; Yamamoto T; Honda Y; Imajo K; Ogawa Y; Kessoku T; Kobayashi T; Nogami A; Higurashi T; Kato S; Hosono K; Saito S; Nakajima A
    J Gastroenterol; 2021 Nov; 56(11):1022-1032. PubMed ID: 34601620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low thyroid function is associated with an increased risk of advanced fibrosis in patients with metabolic dysfunction-associated fatty liver disease.
    Fan H; Li L; Liu Z; Zhang P; Wu S; Han X; Chen X; Suo C; Cao L; Zhang T
    BMC Gastroenterol; 2023 Jan; 23(1):3. PubMed ID: 36604612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic Dysfunction-Associated Fatty Liver Disease Predicts Long-term Mortality and Cardiovascular Disease.
    Moon JH; Kim W; Koo BK; Cho NH;
    Gut Liver; 2022 May; 16(3):433-442. PubMed ID: 34635626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonalcoholic Fatty Liver Disease Is Independently Associated with Early Left Ventricular Diastolic Dysfunction in Patients with Type 2 Diabetes.
    Mantovani A; Pernigo M; Bergamini C; Bonapace S; Lipari P; Pichiri I; Bertolini L; Valbusa F; Barbieri E; Zoppini G; Bonora E; Targher G
    PLoS One; 2015; 10(8):e0135329. PubMed ID: 26252899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic dysfunction-associated fatty liver disease is associated with an increase in systolic blood pressure over time: linear mixed-effects model analyses.
    Mori K; Tanaka M; Hosaka I; Mikami T; Endo K; Hanawa N; Ohnishi H; Furuhashi M
    Hypertens Res; 2023 May; 46(5):1110-1121. PubMed ID: 36717630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on the prevalence of complicated atrial arrhythmias, flutter, and fibrillation in patients with reciprocating supraventricular tachycardia before and after successful catheter ablation.
    Miyamoto KJ; Tsuchihashi K; Uno K; Shimoshige SY; Yoshioka N; Doi A; Nakata T; Shimamoto K
    Pacing Clin Electrophysiol; 2001 Jun; 24(6):969-78. PubMed ID: 11449594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Associations of Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction-Associated Fatty Liver Disease With Coronary Artery Calcification: A Cross-Sectional and Longitudinal Cohort Study.
    Sung KC; Yoo TK; Lee MY; Byrne CD; Zheng MH; Targher G
    Arterioscler Thromb Vasc Biol; 2023 Mar; 43(3):482-491. PubMed ID: 36727522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperuricemia is associated with an increased prevalence of paroxysmal atrial fibrillation in patients with type 2 diabetes referred for clinically indicated 24-h Holter monitoring.
    Mantovani A; Rigolon R; Civettini A; Bolzan B; Morani G; Bonapace S; Dugo C; Zoppini G; Bonora E; Targher G
    J Endocrinol Invest; 2018 Feb; 41(2):223-231. PubMed ID: 28711969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperuricemia as an independent risk factor for metabolic dysfunction-associated fatty liver disease in nonobese patients without type 2 diabetes mellitus.
    Liu J; Wang C; Wang YT; Liu JX; Zhou TH; Yao SK; Chen G
    Am J Physiol Endocrinol Metab; 2023 Jul; 325(1):E62-E71. PubMed ID: 37285598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.